Press Releases Zai Lab Limited BOERSE MUENCHEN

Equities

1ZL

US98887Q1040

Market Closed - BOERSE MUENCHEN Other stock markets 20:43:33 08/07/2024 BST			5-day change	1st Jan Change
15.9 ^EUR	0.00%		-1.24%	-34.84%

06-27	Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing	MT
06-20	Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath	06-21	PU
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D	06-11	BU
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	05-22	BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	05-21	AQ
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	05-20	BU
Zai Lab Announces Participation in May and June Investor Conferences	05-16	BU
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China	05-14	BU
Zai Lab Announces Approval of AUGTYRO for Patients with ROS1-positive NSCLC by China's NMPA	05-13	AQ
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA	05-13	BU
Zai Lab : Corporate Presentation	05-09	PU
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates	05-08	BU
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024	04-15	BU
Zai Lab Statement on Executive Management Team's Agreement on Share Activities	04-12	AQ
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities	04-11	BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint	04-02	AQ
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs	04-02	BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...	04-01	BU
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases	03-28	AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	03-27	BU
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors	03-13	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Zai Lab Limited BOERSE MUENCHEN

Equities

1ZL

US98887Q1040

Press Releases

Filters